OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SW8H6G9
| Market Closed - Boerse Frankfurt Warrants 20:40:55 22/05/2024 BST | ||
| 15.06 EUR | -2.78% |
|
| Current month | -25.94% | ||
| 1 month | -23.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 14.9 | -3.81% |
| 21/05/24 | 15.49 | +3.96% |
| 20/05/24 | 14.9 | -1.46% |
| 17/05/24 | 15.12 | -2.83% |
| 16/05/24 | 15.56 | -1.58% |
Real-time Boerse Frankfurt Warrants
Last update May 22, 2024 at 08:40 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SW8H6G |
| ISIN | DE000SW8H6G9 |
| Date issued | 03/04/2024 |
| Strike | 609.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 17.78 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.38 € |
|---|---|
| Lowest since issue | 14.81 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
447.5
USD
Average target price
462.8
USD
Spread / Average Target
+3.41%
- Stock Market
- Certificates
- Certificat
